Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Exagen Inc. - Common Stock
(NQ:
XGN
)
4.490
+0.020 (+0.45%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Exagen Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Exagen Stock Gains As Q2 Financials Surpass Street Expectations
August 10, 2021
Exagen Inc (NASDAQ: XGN) shares are moving after the Company's Q2 2021 revenue increased 43% Y/Y to $12.8 million due to increased testing volumes, beating the...
Via
Benzinga
54 Stocks Moving In Tuesday's Mid-Day Session
August 10, 2021
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) climbed 79.3% to $14.93 after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy...
Via
Benzinga
Exagen Inc. (XGN) Q2 2021 Earnings Call Transcript
August 10, 2021
XGN earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Exagen: Q2 Earnings Insights
August 09, 2021
Shares of Exagen (NASDAQ:XGN) fell after the company reported Q2 results. Quarterly Results Earnings per share were down 40.74% over the past year to ($0.38), which beat the...
Via
Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
August 08, 2021
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...
Via
Benzinga
Exposures
Product Safety
Exagen: Q1 Earnings Insights
May 11, 2021
Shares of Exagen (NASDAQ:XGN) were flat after the company reported Q1 results. Quarterly Results Earnings per share were down 9.09% year over year to ($0.48), which missed the...
Via
Benzinga
Earnings Scheduled For August 9, 2021
August 09, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •...
Via
Benzinga
Earnings Scheduled For May 11, 2021
May 11, 2021
Companies Reporting Before The Bell • Oxford Lane Capital (NASDAQ:OXLC) is estimated to report earnings for its fourth quarter. • ReWalk Robotics (NASDAQ:RWLK) is...
Via
Benzinga
Return On Capital Employed Overview: Exagen
June 18, 2021
In Q1, Exagen (NASDAQ:XGN) posted sales of $10.59 million. Earnings were up 101.63%, but Exagen still reported an overall loss of $5.57 million. In Q4, Exagen brought in $12.67...
Via
Benzinga
Exagen: Return On Capital Employed Insights
June 03, 2021
During Q1, Exagen's (NASDAQ:XGN) reported sales totaled $10.59 million. Despite a 101.63% in earnings, the company posted a loss of $5.57 million. Exagen collected $12.67 million...
Via
Benzinga
62 Biggest Movers From Yesterday
May 13, 2021
Gainers Curis, Inc. (NASDAQ: CRIS) shares surged 65.5% to settle at $16.27 on Wednesday in reaction to updated data from its ongoing open-label, single-arm, Phase 1/2 study of CA...
Via
Benzinga
Exagen Inc. (XGN) Q1 2021 Earnings Call Transcript
May 12, 2021
XGN earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Benzinga's Top Ratings Upgrades, Downgrades For April 15, 2021
April 15, 2021
Upgrades According to JP Morgan, the prior rating for Vipshop Holdings Ltd (NYSE:VIPS) was changed from Neutral to Overweight. In the fourth quarter, Vipshop Holdings...
Via
Benzinga
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
May 11, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV) -...
Via
Benzinga
Exposures
COVID-19
Product Safety
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
May 09, 2021
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came...
Via
Benzinga
Exposures
COVID-19
Product Safety
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.